Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Zentalis Pharmaceuticals Inc (ZNTL)

Zentalis Pharmaceuticals Inc (ZNTL)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,353,669
  • Shares Outstanding, K 46,630
  • Annual Sales, $ 0 K
  • Annual Income, $ -158,730 K
  • 60-Month Beta 2.04
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 4.07
Trade ZNTL with:

Options Overview Details

View History
  • Implied Volatility 77.63% ( -2.26%)
  • Historical Volatility 82.95%
  • IV Percentile 56%
  • IV Rank 45.34%
  • IV High 112.05% on 04/08/22
  • IV Low 49.08% on 08/24/21
  • Put/Call Vol Ratio 0.00
  • Today's Volume 2
  • Volume Avg (30-Day) 51
  • Put/Call OI Ratio 0.22
  • Today's Open Interest 1,383
  • Open Int (30-Day) 1,405

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/22
See More
  • Average Estimate -1.24
  • Number of Estimates 6
  • High Estimate -1.08
  • Low Estimate -1.32
  • Prior Year -1.34
  • Growth Rate Est. (year over year) +7.46%

Price Performance

See More
Period Period Low Period High Performance
1-Month
20.06 +44.72%
on 06/14/22
29.29 -0.89%
on 06/30/22
+5.39 (+22.80%)
since 06/01/22
3-Month
17.33 +67.51%
on 05/12/22
52.85 -45.07%
on 04/05/22
-17.55 (-37.68%)
since 04/01/22
52-Week
17.33 +67.51%
on 05/12/22
87.19 -66.70%
on 11/04/21
-22.50 (-43.66%)
since 07/01/21

Most Recent Stories

More News
Zentalis Pharmaceuticals Appoints Andrea Paul as General Counsel and Corporate Secretary

NEW YORK and SAN DIEGO, June 27, 2022 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company...

ZNTL : 29.03 (+3.31%)
Zentalis Pharmaceuticals Appoints Andrea Paul as General Counsel and Corporate Secretary

NEW YORK and SAN DIEGO, June 27, 2022 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company...

ZNTL : 29.03 (+3.31%)
Zentalis Pharmaceuticals Promotes Cofounder Cam Gallagher to President

NEW YORK and SAN DIEGO, May 31, 2022 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company...

ZNTL : 29.03 (+3.31%)
Zentalis Pharmaceuticals Announces Closing of Underwritten Offering of Common Stock

NEW YORK and SAN DIEGO, May 18, 2022 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company...

ZNTL : 29.03 (+3.31%)
Advanced Clinical Trials Focus on Development of Vaccines to Prevent Ovarian Cancer Progression

Palm Beach, FL – May 18, 2022 – FinancialNewsMedia.com News Commentary – Companies in the Ovarian Cancer market are spending a lot of R&D on vaccine development, therapies and studies. For the past...

BIOV.CN : 0.100 (-4.76%)
BVAXF : 0.0850 (+6.25%)
CLSN : 1.9300 (+4.89%)
IMGN : 4.61 (+2.44%)
ZNTL : 29.03 (+3.31%)
BMY : 76.84 (-0.21%)
Zentalis Pharmaceuticals Announces Pricing of Underwritten Offering of Common Stock

NEW YORK and SAN DIEGO, May 16, 2022 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company...

ZNTL : 29.03 (+3.31%)
Zentalis Pharmaceuticals Reports First Quarter 2022 Financial Results and Operational Update

Announced initial data on ZN-c3 in combination with chemotherapy in advanced ovarian cancer and interim data on ZN-c3 in uterine serous carcinoma (USC) at...

ZNTL : 29.03 (+3.31%)
Zentalis Pharmaceuticals Announces $25 Million Equity Investment from Pfizer

Zentalis and Pfizer plan to jointly advance the clinical development of ZN-c3, a selective Wee1 inhibitor designed to induce synthetic lethality in cancer...

ZNTL : 29.03 (+3.31%)
Here's Why Zentalis Pharmaceuticals, Inc. (ZNTL) is Poised for a Turnaround After Losing 50% in 4 Weeks

The heavy selling pressure might have exhausted for Zentalis Pharmaceuticals, Inc. (ZNTL) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall...

ZNTL : 29.03 (+3.31%)
Zentalis Pharmaceuticals Announces Overview of Clinical and Preclinical Data Presented at AACR

ZN-c3 in combination with chemotherapy demonstrated strong anti-tumor activity in a heavily pretreated population, with an ORR of 30.2% across all...

ZNTL : 29.03 (+3.31%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Sell with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It is focused on discovering and developing small molecule therapeutics targeting cancers. The company's lead programs consist of ZN-c5, an oral selective estrogen receptor degrader for estrogen-receptor-positive, HER2-negative...

See More

Key Turning Points

3rd Resistance Point 31.37
2nd Resistance Point 30.31
1st Resistance Point 29.67
Last Price 29.03
1st Support Level 27.97
2nd Support Level 26.91
3rd Support Level 26.27

See More

52-Week High 87.19
Fibonacci 61.8% 60.50
Fibonacci 50% 52.26
Fibonacci 38.2% 44.02
Last Price 29.03
52-Week Low 17.33

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar